GRAIL
@GrailBio
Followers
17K
Following
381
Media
376
Statuses
883
GRAIL's mission is to detect cancer early, when it can be cured. Community Guidelines: https://t.co/x8f9DBN6rT Cancer SIGNAL Podcast: https://t.co/6M8RXSAz8X
California, USA
Joined January 2016
Results from the PATHFINDER 2 study demonstrate the Galleri multi-cancer early detection test helped increase cancer detection more than seven-fold when added to recommended screenings for breast, cervical, colorectal, and lung cancers. Learn more: https://t.co/aM5Lc620j7
#ESMO25
1
13
24
We’re presenting new research at #SUO2025 on biopsy-free detection of residual urothelial carcinoma using cell-free DNA methylation in pre-op urine and plasma samples. Meet us there: https://t.co/DuDdjrj1NQ
0
0
1
Grateful for the opportunity to meet with the leadership of @ConquerCancerFd and @ASCO and discuss our shared commitment to improving outcomes for people affected by cancer. We’re proud to work with organizations like Conquer Cancer and ASCO who are deeply committed to innovation
0
1
8
Today GRAIL reported third quarter 2025 financial results. Learn more: https://t.co/4Z2W0a3HHE
0
3
3
Join us next Thursday for GRAIL’s Analyst Day 2025. Register and watch the live webcast here: https://t.co/4tRnU3pOIC
0
1
4
Send a gift they'll talk about long after the holidays. USDA Prime steaks. Gold box. Dry ice unboxing. Delivered by Christmas. That's how you win the holidays. 6 FREE Petite Ribeyes + FREE shipping ($240 value) on $229+ orders Code SANTA229 🥩
0
1
6
On the latest episode of The Cancer SIGNAL podcast, host Susanna Quinn is joined by Nima Nabavizadeh, MD, from Oregon Health & Science University, to discuss the groundbreaking PATHFINDER 2 study findings. Listen here: https://t.co/eBf1Vk4Qnj
#EarlyCancerDetection #MCED
0
3
9
More than half of new cancers detected by the Galleri multi-cancer early detection test in the PATHFINDER 2 study were in Stages I and II, when cancer can be easier to treat. Learn more: https://t.co/aM5Lc620j7
#ESMO25
1
2
12
In collaboration with the University of Oxford, we presented long-term data from the SYMPLIFY study at #EDxConf25. The study evaluated the Galleri multi-cancer early detection (#MCED) test in people with symptoms possibly linked to cancer. Learn more: https://t.co/NmWQTHiIsl
1
3
7
Today we announced that we have entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $325.0 million, before deducting placement agents’ fees and other expenses. Learn more: https://t.co/UicZWd7Rmw
0
2
6
From Dec 8 to Dec 21, Save Up to 50% on Roborock Vacuums Built for Effortless Cleaning.
0
14
129
70% of cancer deaths are from cancers that do not have recommended screening tests. In the PATHFINDER 2 study, presented at #ESMO25, approximately three-quarters of the cancers detected by Galleri do not have standard of care screening options. Learn more: https://t.co/aM5Lc620j7
1
2
12
Press following #ESMO25: Join the Press Briefing II - today, 12:30-13:15 CEST, as Dr. Nima Nabavizadeh discusses “Safety and Performance of a Multi-Cancer Early Detection (MCED) Test in an Intended-Use Population: Initial Results from the Registrational PATHFINDER 2 Study.”
0
3
7
Coming up tomorrow at #ESMO25 in Berlin - results from the PATHFINDER 2 study. See our press release for more details: https://t.co/aM5Lc620j7
0
3
5
Samsung and GRAIL announce strategic collaboration to bring GRAIL’s Galleri multi-cancer early detection (MCED) test to Asia. Learn more: https://t.co/xjXVEMRIKm
2
6
17
After 20 years of serving her local police department, Darla took a multi-cancer early detection (MCED) test through her insurance company. Despite having no symptoms, her test detected a cancer signal, giving her the chance to take swift action and become cancer free today.
0
2
9
We’re counting down to #ESMO25, where we’ll present results from the largest U.S. interventional multi-cancer early detection (MCED) study. GRAIL’s president, Dr. Josh Ofman, shares what to expect from PATHFINDER 2: https://t.co/EmkRinO2Ep
0
1
7
.@dallascowboys exec Tad Carper took a multi-cancer early detection (MCED) test—which led to an unexpected journey. Hear how early detection shaped his experience and perspective on the latest episode of The Cancer SIGNAL podcast: Apple Podcasts: https://t.co/eftnli99x2
0
1
9
We’re presenting new data from our PATHFINDER 2 study at @myESMO. We are also pleased to be sharing results from our SYMPLIFY and REFLECTION studies at the 2025 Early Detection of Cancer Conference (EDCC). Read more: https://t.co/Cd0fy6CEMD
#ESMO25
0
2
8
All of us at GRAIL are saddened to learn about the passing of Bonnie J. Addario, a fierce advocate who made an indelible impact on countless people impacted by lung cancer. Our thoughts are with her family, friends, and all who knew her.
We mourn the loss of our co-founder, Bonnie J. Addario, an extraordinary leader whose vision, strength, and generosity forever changed the course of lung cancer. Her legacy lives on in all whose lives she touched.
0
1
10
Today GRAIL reported second quarter 2025 financial results. Learn more: https://t.co/K2x6C5MLad
0
2
6
30 agents. Cameras ordered off. @erictrump recounts the moment the raid began.
0
150
771
We will issue second quarter 2025 financial results on Tuesday, August 12, 2025. Register for the live teleconference: https://t.co/ApoLhJgjLV See more details: https://t.co/N6gh1hWNez
0
1
5